1 苏文佳,王树叶.滤泡性淋巴瘤的预后分层和治疗进展.实用肿瘤学杂志,2020,34:189-192. 2 白敏,韩维娥,关涛,等.复发难治滤泡淋巴瘤1例并文献复习.白血病·淋巴瘤,2022,31:371-373. 3 徐姗,苏丹.临床药师参与1例滤泡性淋巴瘤合并丙型肝炎患者免疫化疗方案制订的病例分析[J].中国药房,2018,29(09):1267-1270. 4 中国抗癌协会淋巴瘤专业委员会,中华医学会血液学分会.中国滤泡性淋巴瘤诊断与治疗指南(2020年版).中华血液学杂志,2020,41:537-544. 5 Alig S,Jurinovic V,Esfahani MS,et al.Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models-ScienceDirect.Blood Advances,2020,4:4451-4462. 6 邱立华,郑雅心,张志蓉,等.滤泡淋巴瘤免疫靶向治疗研究进展.中国实验血液学杂志,2022,30:627-630. 7 Pott C,Sehn LH,Belada D,et al.MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.Leukemia,2020,34:522-532. 8 Schuster SJ,Bartlett NL,Assouline S,et al.Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients,including those who are resistant to or relapsing after chimeric antigen receptor T-cell(CAR-T)therapies,and is active in treatment through multiple lines.Blood,2019,134Suppl 1:6. 9 Kienle DL,Stilgenbauer S.Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.Expert Opin Pharmacother,2020,21:917-929. 10 干定云,吴军,周曼,等.PD-L1和sIL-2R在滤泡性淋巴瘤患者中的表达及其临床意义.现代肿瘤医学,2022,30:305-308. 11 Cox MC,Castiello L,Mattei M,et al.Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab:a Phase I Clinical Trial.Clin Cancer Res,2019,25:5231-5241. 12 刘佳鑫,平凌燕,宋玉琴,等.滤泡性淋巴瘤治疗进展.中华转移性肿瘤杂志,2022,5:78-82. 13 高凤华,王先火,张会来.滤泡性淋巴瘤联合用药现状与进展.天津医科大学学报,2023,29:212-217.
